ABSTRACT
The posttransfusion platelet count plays a key role in the assessment of a patient's response to platelet transfusion, and it is affected by the pretransfusion platelet count, dose, and viability of platelets administered, as well as by the dilution of platelets in the patient's blood volume (BV). 1 In addition, clinical factors can negatively affect posttransfusion platelet recovery and survival, including splenomegaly, fever, sepsis, active bleeding, and numerous drugs, such as amphotericin B and vancomycin. 2, 3 In normal conditions, mean (SD) posttransfusion platelet recovery is around 60% (15%) of the dose transfused, while 30% to 35% of the transfused platelets are pooled by the spleen. 4 Several mathematical formulas can be used to evaluate the effectiveness of platelet transfusions expressed as platelet recovery and platelet survival. To assess platelet recovery, calculations use platelet counts 10 to 60 minutes after transfusion, while to determine platelet survival, 18-to 24-hour posttransfusion counts are performed. 5 Methods including the corrected count increment (CCI), 6, 7 percent platelet recovery (PPR), 4, 8 and percentage platelet increment (PPI) 8, 9 correct the posttransfusion platelet count for the dose of platelets transfused and the patient's BV. The posttransfusion platelet increment (PI) is a simple calculation that can be used when the number of transfused platelets or the patient's body surface area (BSA) is unavailable. 10 These equations are objective measures that document adequate response to platelet transfusion and development of a refractory state, which is defined as lack of response in platelet increment after two consecutive transfusions.
We studied 24-hour platelet survival in patients with hematologic diseases transfused with single-donor apheresis platelets using the CCI as the reference method to compare the performance of other available formulas.
Material and Methods

Patient Population
This study was conducted between August 2014 and July 2016 and included consecutive patients from all ages with benign and malignant hematologic disorders who underwent transfusion with single-donor apheresis platelet concentrates (PCs). Exclusion criteria included loss to follow-up at 24 hours posttransfusion, transfusion of PCs prepared from whole-blood units, and incomplete clinical records; data were gathered from electronic and paperbased medical files. A total of 85 patients and 142 platelet transfusion episodes fulfilled the inclusion criteria. The protocol of the study was approved by the institutional review board and ethics committee.
Procedures
Platelets were transfused prophylactically if platelet counts were less than or equal to 10,000/µL or at higher levels for specific clinical indications, such as thrombocytopenia with active bleeding or prior to surgery and in the presence of clinical factors known to decrease platelet transfusion effectiveness, including sepsis, hypotension, fever, and splenomegaly. 12 Bacterial growth was monitored through aerobic and anaerobic culture to ensure that only units not infected were transfused.
Platelet dose was calculated using the following formula 13 :
Platelet dose desired platelet increment blood volu
where blood volume was estimated at 70 mL/kg and F = 0.67, which represents a correction factor for splenic pooling.
The procedures were performed at the apheresis unit of the Hematology Department of Dr José E. González University Hospital in Monterrey, México, using a Trima Accel continuous flow cell separator version 6.0 (Terumo BCT, Lakewood, CO) following standard manufacturer instructions with citrate dextrose solution A as anticoagulant with a 11:1 ratio. Donor selection was performed according to the corresponding Mexican Official Norm 14 and technical manual guidelines for blood collection from the AABB. 15 Apheresis platelet units were stored at a mean (SD) of 22°C (2°C) under continuous gentle agitation at 70 rpm or less for a maximum of 5 days. 14 All apheresis platelets were leukoreduced and transfused using a standard 170-µm filter. Platelet counts at 24 hours posttransfusion were recorded.
Main Outcomes
Response to platelet transfusion was monitored using four different formulas: CCI, PI, PPR, and PPI at 24 hours posttransfusion.
The CCI was calculated as follows 4, 16 : The PI was defined as follows 8, 18 : PI posttransfusion platelet count pretransfusion platelet
The PPR was defined as follows 8, 18 : The PPI was defined as follows 9, 18 : PPI PI L estimated total blood volume (mL
0 67 100 11´ẃ here 0.67 accounts for splenic pooling. The platelet count per bag was calculated by the following formula 19 : 
Review of Clinical Records
Biometric characteristics such as height, weight, body mass index (BMI), BSA, and BV were recorded for all patients. As a secondary analysis, clinical conditions that may have influenced the response to platelet transfusion were documented and analyzed. Splenomegaly found during clinical examination was confirmed through upper abdomen ultrasonography.
Statistical Analysis
Data were analyzed using SPSS (SPSS Statistics for Windows, version 22.0; SPSS, Chicago, IL). Descriptive analysis was performed and results are presented as median and range or mean and SD, if not otherwise stated. Student t test was used to compare means of CCI, PI, PPR, PPI, and the influence of clinical factors in the respective mean values. Clinical variables associated with an inadequate posttransfusion platelet count increment were analyzed by binary logistic regression with 95% confidence intervals (CIs). To consider a posttransfusion platelet count increment as adequate, 24-hour posttransfusion cutoff values were 4,500/µL or more for CCI, 1,20 more than 10,000/µL for PI, 18 and 20% for PPR and PPI. 9, 21 A receiver operating characteristic (ROC) curve analysis was performed in MedCalc v.13 (MedCalc Software, Ostend, Belgium) to determine sensitivity and specificity of the formulas, using the CCI equation as reference. A P value of .05 or less was considered statistically significant.
Results
Patient and Apheresis Platelets Characteristics
A total of 142 platelet transfusions collected by apheresis in 85 patients met inclusion criteria. Forty-eight (56.5%) recipients were males and 37 (43.5%) were females. Median (range) age was 21 years (1-73 years), height was Twenty-three (27%) patients had acute lymphoblastic leukemia, 13 (15.3%) had acute myeloid leukemia, 11 (12.9%) had aplastic anemia, 10 (11.8%) had non-Hodgkin lymphoma, nine (10.6%) had Hodgkin lymphoma, and 19 (22.4%) had miscellaneous hematologic diagnoses. Six (4.2%) platelet transfusions were performed in patients with splenomegaly. Main indication for platelet transfusion was prophylactic (83.8%), with a median of 11,400 platelets/µL (range, 1,000-56,000) prior to the transfusion.
Overall median (range) actual platelet yield was 4.5 (1.75-11.8) × 10 11 per unit and median (range) platelet dose given was 3.16 × 10 11 (1-4.92). Of the total transfused platelets, 80 (56.3%) PCs were ABO compatible, and 130 (91.4%) were transfused within the next 24 hours after collection. Mean storage time was 12 hours (range, 0.5-120 hours).
Response to Platelet Transfusion
Mean (SD) CCI at 24 hours was 11,869/µL (10,125/µL). Means for each of the formulas are shown in ❚Table 1❚. Means of CCI, PPR, PI, and PPI were compared among benign and malignant disorders and are displayed in Table 1 . Mean (SD) CCI at 24 hours posttransfusion for hematologic malignancies (n = 121) was 11,677/µL (9,634/µL) vs 12,204/µL (13,708/µL) in 21 benign diseases (P = .880).
For ABO-compatible transfusions, mean (SD) CCI at 24 hours was 14,070/µL (9,888/µL) vs 9,176/µL (10,253/µL) for ABO-incompatible transfusions (P = .007) ( Table 1) .
As a secondary analysis, we evaluated the influence of clinical factors in the transfusion process at 24 hours posttransfusion by Student t test; some of those clinical factors were sepsis, present in 14 (9.9%) transfusion events, hypotension in 16 (11.3%), amphotericin B in 17 (12.0%), and hematopoietic stem cell transplantation (HSCT) in 95 (66.9%). Other characteristics are shown in ❚Table 2❚. Clinical factors that had a negative effect on posttransfusion increments and significantly influenced outcome for all formulas were sepsis, hypotension during the transfusion, and previous use of amphotericin B. On the contrary, the antecedent of splenectomy had a positive effect on the posttransfusion counts. Male sex was 
ROC Curve Analysis
An ROC curve analysis was performed to compare the formulas, taking as reference the CCI equation and the optimal cutoff value to consider a transfusion as successful, in relation to an adequate response to transfusion as assessed by CCI, and its results are shown in ❚Figure 1❚ and ❚Table 4❚.
Discussion
The CCI formula is the standard used to assess response to platelet transfusion and determine platelet recovery and platelet survival, as well as to diagnose a refractory state. To our knowledge, this is the first report studying the performance of the different published equations for assessment of 24-hour posttransfusion platelet survival, and results demonstrate that available formulas are comparable to CCI.
In our hematology patients, 67% of transfused platelets survived at 24 hours, which compares to 72% in the Trial to Reduce Alloimmunization to Platelets study, 2 underscoring the efficiency of platelet regulatory homeostasis mechanisms that remain functional even in the course of primary severe hematologic diseases.
The reported criterion for successful platelet transfusion for PI is 10,000/µL or more at 24 hours, 18 and the use of ROC curve analysis allowed us to define an optimal PI cutoff value of 15.7 × 10 3 at 24 hours. Likewise, the cutoff value for the PPI equation was 17%, close to the reported 20%. 9 For PPR, it was 11.4%, below the reported 20% to 30%. 10, 13, 21 In addition, we found a sensitivity, specificity, and area under the curve around 90% when comparing the four formulas, documenting their high concordance.
We were able to confirm several of the most relevant known clinical aspects that affect individual response to platelet transfusion and how they affected each of the studied formulas. Among them, in addition to the fact that there is a fixed loss of one-third of transfused platelets by splenic pooling, ABO incompatibility translates into the loss of an additional 30% 22 ; this was confirmed in all formulas. In this regard, ABO incompatibility is associated with reduced platelet posttransfusion counts, 2, 23 and in another study, it represented the most important predictor for platelet survival at 24 hours. 24 It is then important, whenever possible, to ensure ABO compatibility when choosing an apheresis platelet donor in patients with severe hematologic disease.
In our group, male sex was associated with a significant reduction in both CCI and PI. It has been found to be a variable affecting posttransfusion counts, and it is associated with an increased risk of refractoriness 2 ; no such case developed in our patients. Hypotension, the use of the antifungal agent amphotericin, splenectomy, and sepsis were identified as variables affecting posttransfusion increments assessed by all four formulas. Furthermore, sepsis was the most important clinical factor associated with a high risk of inadequate posttransfusion platelet count increment in these patients.
The findings confirm the interchangeable use of the formulas in the assessment of platelet posttransfusion survival in patients with hematologic diseases, a patient population in which most of clinical factors surrounding this indication converge. Through an ordered analysis of performance and detailed examination of platelet increments, it was possible to confirm the importance of 24-hour posttransfusion platelet counts and corroborate the effectiveness of PI, PPR, and PPI equations in comparison to CCI as consistent simple mathematical tools that allow a proper assessment of platelet posttransfusion response. The PI is the simplest to calculate and was reasonably comparable to CCI, PPR, and PPI. This suggests that it can be used as the preferred formula to assess 24-hour platelet transfusion efficiency. 
